{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T10:05:11Z","timestamp":1767866711657,"version":"3.49.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201100030C"],"award-info":[{"award-number":["HHSN272201100030C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI110819"],"award-info":[{"award-number":["U19AI110819"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P30 AI110527"],"award-info":[{"award-number":["P30 AI110527"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI095227"],"award-info":[{"award-number":["U19AI095227"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Development of antiviral drug resistance is a continuous concern for viruses with high mutation rates such as influenza. The use of antiviral drugs targeting host proteins required for viral replication is less likely to result in the selection of resistant viruses than treating with direct-acting antivirals. The iminosugar UV-4B is a host-targeted glucomimetic that inhibits endoplasmic reticulum \u03b1-glucosidase I and II enzymes resulting in improper glycosylation and misfolding of viral glycoproteins. UV-4B has broad-spectrum antiviral activity against diverse viruses including dengue and influenza. To examine the ability of influenza virus to develop resistance against UV-4B, mouse-adapted influenza virus was passaged in mice in the presence or absence of UV-4B and virus isolated from lungs was used to infect the next cohort of mice, for five successive passages. Deep sequencing was performed to identify changes in the viral genome during passaging in the presence or absence of UV-4B. Relatively few minor variants were identified within each virus and the ratio of nonsynonymous to synonymous (dN\/dS) substitutions of minor variants confirmed no apparent positive selection following sustained exposure to UV-4B. Three substitutions (one synonymous in PB2, one nonsynonymous in M and PA each) were specifically enriched (&gt;3%) in UV-4B-treated groups at passage five. Recombinant viruses containing each individual or combinations of these nonsynonymous mutations remained sensitive to UV-4B treatment in mice. Overall, these data provide evidence that there is a high genetic barrier to the generation and selection of escape mutants following exposure to host-targeted iminosugar antivirals.<\/jats:p>","DOI":"10.1038\/s41598-019-43030-y","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T10:05:46Z","timestamp":1558001146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Lack of selective resistance of influenza A virus in presence of host-targeted antiviral, UV-4B"],"prefix":"10.1038","volume":"9","author":[{"given":"Kelly L.","family":"Warfield","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlyn R.","family":"Schaaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa Evans","family":"DeWald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin B.","family":"Spurgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Stavale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Mendenhall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan H.","family":"Shilts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-4539","authenticated-orcid":false,"given":"Timothy B.","family":"Stockwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4505-020X","authenticated-orcid":false,"given":"Dale L.","family":"Barnard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urban","family":"Ramstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman R.","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,16]]},"reference":[{"key":"43030_CR1","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1126\/science.1187816","volume":"328","author":"JD Bloom","year":"2010","unstructured":"Bloom, J. D., Gong, L. I. & Baltimore, D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328, 1272\u20131275, https:\/\/doi.org\/10.1126\/science.1187816 (2010).","journal-title":"Science"},{"key":"43030_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.antiviral.2012.09.013","volume":"96","author":"SM Lee","year":"2012","unstructured":"Lee, S. M. & Yen, H. L. Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection. Antiviral Res 96, 391\u2013404, https:\/\/doi.org\/10.1016\/j.antiviral.2012.09.013 (2012).","journal-title":"Antiviral Res"},{"key":"43030_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nbt0310-239","volume":"28","author":"JY Min","year":"2010","unstructured":"Min, J. Y. & Subbarao, K. Cellular targets for influenza drugs. Nat Biotechnol 28, 239\u2013240, https:\/\/doi.org\/10.1038\/nbt0310-239 (2010).","journal-title":"Nat Biotechnol"},{"issue":"Suppl","key":"43030_CR4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1164\/arrd.1966.93.3P2.162","volume":"93","author":"JF Hers","year":"1966","unstructured":"Hers, J. F. Disturbances of the ciliated epithelium due to influenza virus. Am Rev Respir Dis 93(Suppl), 162\u2013177, https:\/\/doi.org\/10.1164\/arrd.1966.93.3P2.162 (1966).","journal-title":"Am Rev Respir Dis"},{"key":"43030_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.biochem.69.1.531","volume":"69","author":"JJ Skehel","year":"2000","unstructured":"Skehel, J. J. & Wiley, D. C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69, 531\u2013569, https:\/\/doi.org\/10.1146\/annurev.biochem.69.1.531 (2000).","journal-title":"Annu Rev Biochem"},{"key":"43030_CR6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.32607\/20758251-2009-1-2-26-32","volume":"1","author":"YA Shtyrya","year":"2009","unstructured":"Shtyrya, Y. A., Mochalova, L. V. & Bovin, N. V. Influenza virus neuraminidase: structure and function. Acta Naturae 1, 26\u201332 (2009).","journal-title":"Acta Naturae"},{"key":"43030_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1091\/mbc.2.7.549","volume":"2","author":"G Russ","year":"1991","unstructured":"Russ, G., Bennink, J. R., Bachi, T. & Yewdell, J. W. Influenza virus hemagglutinin trimers and monomers maintain distinct biochemical modifications and intracellular distribution in brefeldin A-treated cells. Cell Regul 2, 549\u2013563, https:\/\/doi.org\/10.1091\/mbc.2.7.549 (1991).","journal-title":"Cell Regul"},{"key":"43030_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0092-8674(88)90426-6","volume":"52","author":"JW Yewdell","year":"1988","unstructured":"Yewdell, J. W., Yellen, A. & Bachi, T. Monoclonal antibodies localize events in the folding, assembly, and intracellular transport of the influenza virus hemagglutinin glycoprotein. Cell 52, 843\u2013852 (1988).","journal-title":"Cell"},{"key":"43030_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S1097-2765(02)00821-3","volume":"11","author":"R Daniels","year":"2003","unstructured":"Daniels, R., Kurowski, B., Johnson, A. E. & Hebert, D. N. N-linked glycans direct the cotranslational folding pathway of influenza hemagglutinin. Mol Cell 11, 79\u201390 (2003).","journal-title":"Mol Cell"},{"key":"43030_CR10","doi-asserted-by":"publisher","first-page":"E1417","DOI":"10.1073\/pnas.1108754108","volume":"108","author":"SR Das","year":"2011","unstructured":"Das, S. R. et al. Fitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion strategy. Proc Natl Acad Sci USA 108, E1417\u20131422, https:\/\/doi.org\/10.1073\/pnas.1108754108 (2011).","journal-title":"Proc Natl Acad Sci USA"},{"key":"43030_CR11","doi-asserted-by":"publisher","first-page":"e1001211","DOI":"10.1371\/journal.ppat.1001211","volume":"6","author":"SR Das","year":"2010","unstructured":"Das, S. R. et al. Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain. PLoS Pathog 6, e1001211, https:\/\/doi.org\/10.1371\/journal.ppat.1001211 (2010).","journal-title":"PLoS Pathog"},{"key":"43030_CR12","doi-asserted-by":"publisher","first-page":"12467","DOI":"10.1073\/pnas.1208138109","volume":"109","author":"Y Han","year":"2012","unstructured":"Han, Y. et al. Monitoring cotranslational protein folding in mammalian cells at codon resolution. Proc Natl Acad Sci USA 109, 12467\u201312472, https:\/\/doi.org\/10.1073\/pnas.1208138109 (2012).","journal-title":"Proc Natl Acad Sci USA"},{"key":"43030_CR13","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/0092-8674(86)90076-0","volume":"46","author":"MJ Gething","year":"1986","unstructured":"Gething, M. J., McCammon, K. & Sambrook, J. Expression of wild-type and mutant forms of influenza hemagglutinin: the role of folding in intracellular transport. Cell 46, 939\u2013950 (1986).","journal-title":"Cell"},{"key":"43030_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0092-8674(88)90381-9","volume":"53","author":"CS Copeland","year":"1988","unstructured":"Copeland, C. S. et al. Folding, trimerization, and transport are sequential events in the biogenesis of influenza virus hemagglutinin. Cell 53, 197\u2013209 (1988).","journal-title":"Cell"},{"key":"43030_CR15","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1083\/jcb.103.4.1179","volume":"103","author":"CS Copeland","year":"1986","unstructured":"Copeland, C. S., Doms, R. W., Bolzau, E. M., Webster, R. G. & Helenius, A. Assembly of influenza hemagglutinin trimers and its role in intracellular transport. J Cell Biol 103, 1179\u20131191 (1986).","journal-title":"J Cell Biol"},{"key":"43030_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1750-2659.2011.00304.x","volume":"6","author":"GM Air","year":"2012","unstructured":"Air, G. M. Influenza neuraminidase. Influenza Other Respir Viruses 6, 245\u2013256, https:\/\/doi.org\/10.1111\/j.1750-2659.2011.00304.x (2012).","journal-title":"Influenza Other Respir Viruses"},{"key":"43030_CR17","doi-asserted-by":"publisher","first-page":"28265","DOI":"10.1074\/jbc.M501020200","volume":"280","author":"M Pieren","year":"2005","unstructured":"Pieren, M., Galli, C., Denzel, A. & Molinari, M. The use of calnexin and calreticulin by cellular and viral glycoproteins. J Biol Chem 280, 28265\u201328271, https:\/\/doi.org\/10.1074\/jbc.M501020200 (2005).","journal-title":"J Biol Chem"},{"key":"43030_CR18","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1073\/pnas.91.3.913","volume":"91","author":"C Hammond","year":"1994","unstructured":"Hammond, C., Braakman, I. & Helenius, A. Role of N-linked oligosaccharide recognition, glucose trimming, and calnexin in glycoprotein folding and quality control. Proc Natl Acad Sci USA 91, 913\u2013917 (1994).","journal-title":"Proc Natl Acad Sci USA"},{"key":"43030_CR19","doi-asserted-by":"publisher","first-page":"E4630","DOI":"10.1073\/pnas.1604463113","volume":"113","author":"AT Caputo","year":"2016","unstructured":"Caputo, A. T. et al. Structures of mammalian ER alpha-glucosidase II capture the binding modes of broad-spectrum iminosugar antivirals. Proc Natl Acad Sci USA 113, E4630\u20134638, https:\/\/doi.org\/10.1073\/pnas.1604463113 (2016).","journal-title":"Proc Natl Acad Sci USA"},{"key":"43030_CR20","doi-asserted-by":"publisher","first-page":"1235681","DOI":"10.1126\/science.1235681","volume":"343","author":"M Dalziel","year":"2014","unstructured":"Dalziel, M., Crispin, M., Scanlan, C. N., Zitzmann, N. & Dwek, R. A. Emerging principles for the therapeutic exploitation of glycosylation. Science 343, 1235681, https:\/\/doi.org\/10.1126\/science.1235681 (2014).","journal-title":"Science"},{"key":"43030_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-981-10-8727-1_20","volume":"1062","author":"JL Miller","year":"2018","unstructured":"Miller, J. L., Tyrrell, B. E. & Zitzmann, N. Mechanisms of Antiviral Activity of Iminosugars Against Dengue Virus. Adv Exp Med Biol 1062, 277\u2013301, https:\/\/doi.org\/10.1007\/978-981-10-8727-1_20 (2018).","journal-title":"Adv Exp Med Biol"},{"key":"43030_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/1040841X.2016.1242868","volume":"43","author":"BE Tyrrell","year":"2017","unstructured":"Tyrrell, B. E., Sayce, A. C., Warfield, K. L., Miller, J. L. & Zitzmann, N. Iminosugars: Promising therapeutics for influenza infection. Crit Rev Microbiol 43, 521\u2013545, https:\/\/doi.org\/10.1080\/1040841X.2016.1242868 (2017).","journal-title":"Crit Rev Microbiol"},{"key":"43030_CR23","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1042\/BST20160182","volume":"45","author":"DS Alonzi","year":"2017","unstructured":"Alonzi, D. S., Scott, K. A., Dwek, R. A. & Zitzmann, N. Iminosugar antivirals: the therapeutic sweet spot. Biochem Soc Trans 45, 571\u2013582, https:\/\/doi.org\/10.1042\/BST20160182 (2017).","journal-title":"Biochem Soc Trans"},{"key":"43030_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/v8030071","volume":"8","author":"KL Warfield","year":"2016","unstructured":"Warfield, K. L. et al. The Iminosugar UV-4 is a Broad Inhibitor of Influenza A and B Viruses ex Vivo and in Mice. Viruses 8, 71, https:\/\/doi.org\/10.3390\/v8030071 (2016).","journal-title":"Viruses"},{"key":"43030_CR25","doi-asserted-by":"publisher","first-page":"e0121662","DOI":"10.1371\/journal.pone.0121662","volume":"10","author":"EJ Stavale","year":"2015","unstructured":"Stavale, E. J., Vu, H., Sampath, A., Ramstedt, U. & Warfield, K. L. In vivo therapeutic protection against influenza A (H1N1) oseltamivir-sensitive and resistant viruses by the iminosugar UV-4. PLoS One 10, e0121662, https:\/\/doi.org\/10.1371\/journal.pone.0121662 (2015).","journal-title":"PLoS One"},{"key":"43030_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.antiviral.2016.03.001","volume":"129","author":"KL Warfield","year":"2016","unstructured":"Warfield, K. L. et al. Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by the iminosugar UV-4. Antiviral Res 129, 93\u201398, https:\/\/doi.org\/10.1016\/j.antiviral.2016.03.001 (2016).","journal-title":"Antiviral Res"},{"key":"43030_CR27","doi-asserted-by":"publisher","first-page":"5592","DOI":"10.1128\/JVI.00028-15","volume":"89","author":"E Plummer","year":"2015","unstructured":"Plummer, E. et al. Dengue Virus Evolution under a Host-Targeted Antiviral. J Virol 89, 5592\u20135601, https:\/\/doi.org\/10.1128\/JVI.00028-15 (2015).","journal-title":"J Virol"},{"key":"43030_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.antiviral.2013.01.004","volume":"98","author":"ST Perry","year":"2013","unstructured":"Perry, S. T. et al. An iminosugar with potent inhibition of dengue virus infection in vivo. Antiviral Res 98, 35\u201343, https:\/\/doi.org\/10.1016\/j.antiviral.2013.01.004 (2013).","journal-title":"Antiviral Res"},{"key":"43030_CR29","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nature15379","volume":"526","author":"SS Lakdawala","year":"2015","unstructured":"Lakdawala, S. S. et al. The soft palate is an important site of adaptation for transmissible influenza viruses. Nature 526, 122\u2013125, https:\/\/doi.org\/10.1038\/nature15379 (2015).","journal-title":"Nature"},{"key":"43030_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ng.3479","volume":"48","author":"LL Poon","year":"2016","unstructured":"Poon, L. L. et al. Quantifying influenza virus diversity and transmission in humans. Nat Genet 48, 195\u2013200, https:\/\/doi.org\/10.1038\/ng.3479 (2016).","journal-title":"Nat Genet"},{"key":"43030_CR31","doi-asserted-by":"publisher","first-page":"W186","DOI":"10.1093\/nar\/gks528","volume":"40","author":"S Wang","year":"2012","unstructured":"Wang, S., Sundaram, J. P. & Stockwell, T. B. VIGOR extended to annotate genomes for additional 12 different viruses. Nucleic Acids Res 40, W186\u2013192, https:\/\/doi.org\/10.1093\/nar\/gks528 (2012).","journal-title":"Nucleic Acids Res"},{"key":"43030_CR32","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1128\/AAC.02956-14","volume":"58","author":"A Pizzorno","year":"2014","unstructured":"Pizzorno, A. et al. Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice. Antimicrob Agents Chemother 58, 6398\u20136405, https:\/\/doi.org\/10.1128\/AAC.02956-14 (2014).","journal-title":"Antimicrob Agents Chemother"},{"key":"43030_CR33","doi-asserted-by":"publisher","first-page":"185ra168","DOI":"10.1126\/scitranslmed.3006368","volume":"5","author":"PR Dormitzer","year":"2013","unstructured":"Dormitzer, P. R. et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med 5, 185ra168, https:\/\/doi.org\/10.1126\/scitranslmed.3006368 (2013).","journal-title":"Sci Transl Med"},{"key":"43030_CR34","doi-asserted-by":"publisher","first-page":"10309","DOI":"10.1128\/JVI.01109-09","volume":"83","author":"B Zhou","year":"2009","unstructured":"Zhou, B. et al. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza a viruses. J Virol 83, 10309\u201310313, https:\/\/doi.org\/10.1128\/JVI.01109-09 (2009).","journal-title":"J Virol"},{"key":"43030_CR35","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jviromet.2011.01.021","volume":"173","author":"B Zhou","year":"2011","unstructured":"Zhou, B. et al. Reverse genetics plasmid for cloning unstable influenza A virus gene segments. J Virol Methods 173, 378\u2013383, https:\/\/doi.org\/10.1016\/j.jviromet.2011.01.021 (2011).","journal-title":"J Virol Methods"},{"key":"43030_CR36","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.coviro.2012.08.004","volume":"2","author":"M Gotte","year":"2012","unstructured":"Gotte, M. The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance. Curr Opin Virol 2, 644\u2013650, https:\/\/doi.org\/10.1016\/j.coviro.2012.08.004 (2012).","journal-title":"Curr Opin Virol"},{"key":"43030_CR37","doi-asserted-by":"publisher","first-page":"e1006796","DOI":"10.1371\/journal.ppat.1006796","volume":"14","author":"I Kosik","year":"2018","unstructured":"Kosik, I. et al. Influenza A virus hemagglutinin glycosylation compensates for antibody escape fitness costs. PLoS Pathog 14, e1006796, https:\/\/doi.org\/10.1371\/journal.ppat.1006796 (2018).","journal-title":"PLoS Pathog"},{"key":"43030_CR38","doi-asserted-by":"publisher","first-page":"7590","DOI":"10.1128\/JVI.01623-05","volume":"80","author":"P Baccam","year":"2006","unstructured":"Baccam, P., Beauchemin, C., Macken, C. A., Hayden, F. G. & Perelson, A. S. Kinetics of influenza A virus infection in humans. J Virol 80, 7590\u20137599, https:\/\/doi.org\/10.1128\/JVI.01623-05 (2006).","journal-title":"J Virol"},{"key":"43030_CR39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.antiviral.2018.07.001","volume":"157","author":"A Lackenby","year":"2018","unstructured":"Lackenby, A. et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016\u20132017. Antiviral Res 157, 38\u201346, https:\/\/doi.org\/10.1016\/j.antiviral.2018.07.001 (2018).","journal-title":"Antiviral Res"},{"key":"43030_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0166-3542(00)00125-X","volume":"48","author":"RW Sidwell","year":"2000","unstructured":"Sidwell, R. W. & Smee, D. F. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res 48, 1\u201316 (2000).","journal-title":"Antiviral Res"},{"key":"43030_CR41","unstructured":"Centers for Disease Control and Prevention, N. C. f. I. a. R. D. N. Influenza Antiviral Drug Resistance."},{"key":"43030_CR42","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/226082a0","volume":"226","author":"JS Oxford","year":"1970","unstructured":"Oxford, J. S., Logan, I. S. & Potter, C. W. In vivo selection of an influenza A2 strain resistant to amantadine. Nature 226, 82\u201383 (1970).","journal-title":"Nature"},{"key":"43030_CR43","doi-asserted-by":"crossref","unstructured":"Monto, A. S. & Arden, N. H. Implications of viral resistance to amantadine in control of influenza A. Clin Infect Dis 15, 362\u2013367, discussion 368\u2013369 (1992).","DOI":"10.1093\/clinids\/15.2.362"},{"key":"43030_CR44","first-page":"119","volume":"176","author":"FG Hayden","year":"1992","unstructured":"Hayden, F. G. & Hay, A. J. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 176, 119\u2013130 (1992).","journal-title":"Curr Top Microbiol Immunol"},{"key":"43030_CR45","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJM198912213212502","volume":"321","author":"FG Hayden","year":"1989","unstructured":"Hayden, F. G. et al. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 321, 1696\u20131702, https:\/\/doi.org\/10.1056\/NEJM198912213212502 (1989).","journal-title":"N Engl J Med"},{"key":"43030_CR46","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/jvi.67.6.2972-2980.1993","volume":"67","author":"PM Colman","year":"1993","unstructured":"Colman, P. M., Hoyne, P. A. & Lawrence, M. C. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol 67, 2972\u20132980 (1993).","journal-title":"J Virol"},{"key":"43030_CR47","doi-asserted-by":"publisher","first-page":"ofx105","DOI":"10.1093\/ofid\/ofx105","volume":"4","author":"Y Abed","year":"2017","unstructured":"Abed, Y. & Boivin, G. A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir. Open Forum Infect Dis 4, ofx105, https:\/\/doi.org\/10.1093\/ofid\/ofx105 (2017).","journal-title":"Open Forum Infect Dis"},{"key":"43030_CR48","doi-asserted-by":"publisher","first-page":"e15190","DOI":"10.1371\/journal.pone.0015190","volume":"6","author":"SE Hensley","year":"2011","unstructured":"Hensley, S. E. et al. Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance. PLoS One 6, e15190, https:\/\/doi.org\/10.1371\/journal.pone.0015190 (2011).","journal-title":"PLoS One"},{"key":"43030_CR49","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1177\/135965350501000805","volume":"10","author":"L Barroso","year":"2005","unstructured":"Barroso, L., Treanor, J., Gubareva, L. & Hayden, F. G. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther 10, 901\u2013910 (2005).","journal-title":"Antivir Ther"},{"issue":"Suppl 1","key":"43030_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-199936001-00001","volume":"36","author":"LM Cass","year":"1999","unstructured":"Cass, L. M., Efthymiopoulos, C. & Bye, A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 36(Suppl 1), 1\u201311 (1999).","journal-title":"Clin Pharmacokinet"},{"key":"43030_CR51","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1098\/rstb.2001.1021","volume":"356","author":"M Elliott","year":"2001","unstructured":"Elliott, M. Zanamivir: from drug design to the clinic. Philos Trans R Soc Lond B Biol Sci 356, 1885\u20131893, https:\/\/doi.org\/10.1098\/rstb.2001.1021 (2001).","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"Suppl 2","key":"43030_CR52","doi-asserted-by":"publisher","first-page":"ii5","DOI":"10.1093\/jac\/dkq015","volume":"65","author":"BE Davies","year":"2010","unstructured":"Davies, B. E. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother 65(Suppl 2), ii5\u2013ii10, https:\/\/doi.org\/10.1093\/jac\/dkq015 (2010).","journal-title":"J Antimicrob Chemother"},{"key":"43030_CR53","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2165\/00002018-200326110-00004","volume":"26","author":"R Dutkowski","year":"2003","unstructured":"Dutkowski, R. et al. Safety and pharmacology of oseltamivir in clinical use. Drug Saf 26, 787\u2013801 (2003).","journal-title":"Drug Saf"},{"key":"43030_CR54","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2165\/00003088-199937060-00003","volume":"37","author":"G He","year":"1999","unstructured":"He, G., Massarella, J. & Ward, P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 37, 471\u2013484, https:\/\/doi.org\/10.2165\/00003088-199937060-00003 (1999).","journal-title":"Clin Pharmacokinet"},{"key":"43030_CR55","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1021\/jm980162u","volume":"41","author":"CU Kim","year":"1998","unstructured":"Kim, C. U. et al. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J Med Chem 41, 2451\u20132460, https:\/\/doi.org\/10.1021\/jm980162u (1998).","journal-title":"J Med Chem"},{"key":"43030_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-127","volume":"13","author":"CP Pollara","year":"2013","unstructured":"Pollara, C. P. et al. Nosocomial outbreak of the pandemic Influenza A (H1N1) 2009 in critical hematologic patients during seasonal influenza 2010\u20132011: detection of oseltamivir resistant variant viruses. BMC Infect Dis 13, 127, https:\/\/doi.org\/10.1186\/1471-2334-13-127 (2013).","journal-title":"BMC Infect Dis"},{"key":"43030_CR57","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1128\/AAC.00555-08","volume":"52","author":"TG Sheu","year":"2008","unstructured":"Sheu, T. G. et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 52, 3284\u20133292, https:\/\/doi.org\/10.1128\/AAC.00555-08 (2008).","journal-title":"Antimicrob Agents Chemother"},{"key":"43030_CR58","doi-asserted-by":"publisher","first-page":"e37095","DOI":"10.1371\/journal.pone.0037095","volume":"7","author":"J LeGoff","year":"2012","unstructured":"LeGoff, J. et al. I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y. PLoS One 7, e37095, https:\/\/doi.org\/10.1371\/journal.pone.0037095 (2012).","journal-title":"PLoS One"},{"key":"43030_CR59","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1128\/AAC.05994-11","volume":"56","author":"A Pizzorno","year":"2012","unstructured":"Pizzorno, A. et al. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus. Antimicrob Agents Chemother 56, 1208\u20131214, https:\/\/doi.org\/10.1128\/AAC.05994-11 (2012).","journal-title":"Antimicrob Agents Chemother"},{"key":"43030_CR60","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3201\/eid1801.111079","volume":"18","author":"AC Hurt","year":"2012","unstructured":"Hurt, A. C., Leang, S. K., Speers, D. J., Barr, I. G. & Maurer-Stroh, S. Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses. Emerg Infect Dis 18, 109\u2013112, https:\/\/doi.org\/10.3201\/eid1801.111079 (2012).","journal-title":"Emerg Infect Dis"},{"key":"43030_CR61","doi-asserted-by":"crossref","unstructured":"Hurt, A. C. et al. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill 16 (2011).","DOI":"10.2807\/ese.16.23.19884-en"},{"key":"43030_CR62","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/jac\/dku349","volume":"70","author":"S Hussain","year":"2015","unstructured":"Hussain, S. et al. Strain-specific antiviral activity of iminosugars against human influenza A viruses. J Antimicrob Chemother 70, 136\u2013152, https:\/\/doi.org\/10.1093\/jac\/dku349 (2015).","journal-title":"J Antimicrob Chemother"},{"key":"43030_CR63","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.chom.2013.02.008","volume":"13","author":"SR Das","year":"2013","unstructured":"Das, S. R. et al. Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection. Cell Host Microbe 13, 314\u2013323, https:\/\/doi.org\/10.1016\/j.chom.2013.02.008 (2013).","journal-title":"Cell Host Microbe"},{"key":"43030_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-9-5","volume":"9","author":"A Djikeng","year":"2008","unstructured":"Djikeng, A. et al. Viral genome sequencing by random priming methods. BMC Genomics 9, 5, https:\/\/doi.org\/10.1186\/1471-2164-9-5 (2008).","journal-title":"BMC Genomics"},{"key":"43030_CR65","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1093\/nar\/gkr344","volume":"39","author":"K Nakamura","year":"2011","unstructured":"Nakamura, K. et al. Sequence-specific error profile of Illumina sequencers. Nucleic Acids Res 39, e90, https:\/\/doi.org\/10.1093\/nar\/gkr344 (2011).","journal-title":"Nucleic Acids Res"},{"key":"43030_CR66","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1126\/science.1183173","volume":"327","author":"V Doceul","year":"2010","unstructured":"Doceul, V., Hollinshead, M., van der Linden, L. & Smith, G. L. Repulsion of superinfecting virions: a mechanism for rapid virus spread. Science 327, 873\u2013876, https:\/\/doi.org\/10.1126\/science.1183173 (2010).","journal-title":"Science"},{"key":"43030_CR67","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-1-61779-621-0_11","volume":"865","author":"B Zhou","year":"2012","unstructured":"Zhou, B. & Wentworth, D. E. Influenza A virus molecular virology techniques. Methods Mol Biol 865, 175\u2013192, https:\/\/doi.org\/10.1007\/978-1-61779-621-0_11 (2012).","journal-title":"Methods Mol Biol"},{"key":"43030_CR68","first-page":"493","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty percent endpoints. The American Journal of Hygiene 27, 493\u2013497 (1938).","journal-title":"The American Journal of Hygiene"},{"key":"43030_CR69","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/j.1749-6632.1957.tb49710.x","volume":"69","author":"WR Bryan","year":"1957","unstructured":"Bryan, W. R. Interpretation of host response in quantitative studies on animal viruses. Ann N Y Acad Sci 69, 698\u2013728 (1957).","journal-title":"Ann N Y Acad Sci"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43030-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43030-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43030-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T09:44:43Z","timestamp":1671270283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43030-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,16]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["43030"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-43030-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,16]]},"assertion":[{"value":"7 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.W., E.S., M.M., K.R.S., M.H.S., T.B.S. and D.L.B. declare no competing interests. K.L.W., L.E.D. and K.B.S. are employees and shareholders of Emergent BioSolutions. K.L.W. and U.R. are authors on pending and issued patents related to the use of iminosugars as treatments for viral disease. S.R.D. has been funded by Emergent BioSolutions. Other authors have no competing financial and\/or non-financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"7484"}}